



COMPANY CONTACT:

Endologix, Inc.
Paul McCormick
President and CEO
(949) 595-7200
www.endologix.com

INVESTOR CONTACTS:

Lippert/Heilshorn & Associates, Inc.
Bruce Voss (bvoss@lhai.com)
Jody Cain (jcain@lhai.com)
(310) 691-7100
www.lhai.com

**ENDOLOGIX ANNOUNCES THE PRESENTATION OF FAVORABLE
POWERLINK SYSTEM CLINICAL DATA AT 2007 VEITH SYMPOSIUM**

IRVINE, Calif. (November 20, 2007) – Endologix, Inc. (Nasdaq: ELGX) today reported that favorable Powerlink® System clinical data was featured in two presentations on Saturday, November 17 at the 34th Annual VEITH Symposium in New York City. The presentations by Professor Dieter Raithel, M.D., Southern Clinic in Nuremburg, Germany, and Jeffrey Carpenter, M.D., University of Pennsylvania School of Medicine, are available on the Endologix Web site at http://www.endologix.com/health_clinical_presentations.php.

In his presentation "Why is the Endologix Powerlink Endograft with Fixation on the Aortic Bifurcation Best for Most AAAs?," Professor Raithel reported that the Powerlink's unique design characteristics make it superior in treating patients with aneurysm anatomy deemed unsuitable for other stent grafts. His conclusion was based on his experience with 1,492 stent graft procedures, including 492 Powerlink System cases over an 8½ year period. He stated that the Powerlink System is a critical component of his armamentarium that allows him to treat more than 90% of all eligible AAA patients with a stent graft.

Dr. Carpenter, in his presentation "Composite Endografts for Wide Neck EVAR," reported on his experience utilizing the bifurcated Powerlink System as the primary treatment device in conjunction with larger commercially available accessories to treat AAA patients with wide aortic necks. He concluded that the Powerlink bifurcated stent graft's long main body and the small french size of its delivery catheter facilitated this composite approach.

"We believe the positive experience of these leading clinicians provides growing clinical support that the Powerlink System is capable of treating the continuously increasing number of patients seeking minimally invasive AAA repair options," said Paul McCormick, president and chief executive officer of Endologix. "While we are seeing strong growth in the use of stent grafts through better devices and favorable demographics, open repair remains a significant clinical alternative for many clinicians due to the limitations and results of the early generation devices. These presentations underscore the fact that the Powerlink System provides important technology that can meet the expanding role of EVAR and we are exceptionally pleased that this message was delivered at the prestigious VEITH Symposium."

About Endologix

Endologix, Inc. develops and manufactures minimally invasive treatments for vascular diseases. Endologix's Powerlink System is an endoluminal stent graft (ELG) for treating abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it the thirteenth leading cause of death in the U.S. Additional information can be found on Endologix's Web site at www.endologix.com.

Except for historical information contained herein, this news release contains forward-looking statements, including with respect to continuing clinical acceptance of the Company's products,, the accuracy of which are necessarily subject to risks and uncertainties, all of which are difficult or impossible to predict accurately and many of which are beyond the control of Endologix. The Company undertakes no obligation to update its forward looking statements. Please refer to the Company's Annual Report on Form 10-K for the year ended December 31, 2006, and the Company's other filings with the Securities and Exchange Commission, for more detailed information regarding these risks and other factors that may cause actual results to differ materially from those expressed or implied.

#